MeSH term
Frequency | Condition_Probility | Amino Acid Sequence | 12 | 0.0 |
Animals | 20 | 0.0 |
Complement 1/*metabolism | 11 | 42.0 |
Complement 1q/metabolism | 2 | 8.0 |
Complement Pathway, Classical/*physiology | 3 | 27.0 |
Humans | 108 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Rats | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 54 | 0.0 |
Base Sequence | 6 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Collectins | 2 | 2.0 |
Complement/metabolism | 2 | 2.0 |
Complement Activation | 5 | 1.0 |
Disulfides | 2 | 2.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 13 | 0.0 |
Glycosylation | 3 | 0.0 |
Kinetics | 13 | 0.0 |
Protein Binding | 7 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Cell Line | 5 | 0.0 |
Cells, Cultured | 12 | 0.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Umbilical Veins | 2 | 0.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
Chromatography, Gel | 2 | 0.0 |
Complement 1r/metabolism | 2 | 50.0 |
Complement 1s/metabolism | 3 | 25.0 |
Osmolar Concentration | 5 | 0.0 |
Adult | 18 | 0.0 |
Aged | 13 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Alzheimer Disease/*metabolism | 2 | 0.0 |
Complement Activation/*physiology | 2 | 8.0 |
Female | 29 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Male | 24 | 0.0 |
Middle Aged | 15 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Reference Values | 3 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Complement 1q/*metabolism | 3 | 15.0 |
Research Support, U.S. Gov't, P.H.S. | 31 | 0.0 |
Solubility | 3 | 0.0 |
Blotting, Western | 4 | 0.0 |
Gene Expression | 2 | 0.0 |
Molecular Weight | 10 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Protein Conformation | 9 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Substrate Specificity | 3 | 0.0 |
Complement/*metabolism | 3 | 1.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
Complement 1s/*metabolism | 4 | 57.0 |
Complement/*biosynthesis/genetics | 3 | 37.0 |
Mice | 4 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Complement/*analysis/immunology | 2 | 22.0 |
Disease Progression | 2 | 0.0 |
Complement 1 Inactivators/analysis | 2 | 22.0 |
Monocytes/*metabolism | 2 | 0.0 |
Complement 1q/biosynthesis | 2 | 66.0 |
Complement 1s/biosynthesis | 3 | 100.0 |
Complement 2/biosynthesis | 3 | 18.0 |
Complement 4/biosynthesis | 2 | 12.0 |
*Complement Pathway, Classical | 5 | 5.0 |
Immunoenzyme Techniques | 3 | 0.0 |
*Complement Activation | 7 | 1.0 |
Autoradiography | 2 | 0.0 |
Complement 1r/biosynthesis | 2 | 100.0 |
Complement 3/biosynthesis | 2 | 7.0 |
Complement Factor B/biosynthesis | 2 | 11.0 |
Fibroblasts/metabolism | 4 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Comparative Study | 9 | 0.0 |
Complement 1 Inactivators/*metabolism | 3 | 33.0 |
Complement 1r/*metabolism | 2 | 28.0 |
Kallikreins/metabolism | 2 | 13.0 |
Rabbits | 5 | 0.0 |
Acute Disease | 2 | 0.0 |
Adolescent | 7 | 0.0 |
Hemolytic Plaque Technique | 3 | 5.0 |
Immunoglobulins/analysis | 4 | 1.0 |
DNA Probes | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
Liver Neoplasms | 2 | 0.0 |
Skin/*metabolism | 2 | 1.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Binding Sites | 8 | 0.0 |
Complement/*biosynthesis | 3 | 8.0 |
Epithelium/metabolism | 2 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Complement/*deficiency | 2 | 4.0 |
Complement 1/deficiency | 2 | 40.0 |
Complement 2/deficiency | 2 | 8.0 |
Complement 4/deficiency | 2 | 8.0 |
Complement Pathway, Alternative | 4 | 3.0 |
Complement Pathway, Classical | 3 | 2.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Hydrolysis | 3 | 0.0 |
In Vitro | 5 | 0.0 |
Macromolecular Substances | 10 | 0.0 |
Thermodynamics | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Epitopes | 3 | 0.0 |
Immunodiffusion | 7 | 2.0 |
English Abstract | 4 | 0.0 |
Complement 2/*metabolism | 2 | 11.0 |
Lupus Erythematosus, Systemic/*immunology | 4 | 2.0 |
Enzyme Activation | 3 | 0.0 |
Plasmin/pharmacology | 2 | 11.0 |
Guinea Pigs | 5 | 0.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Lupus Erythematosus, Systemic/immunology | 2 | 1.0 |
*Complement 1 | 6 | 66.0 |
Precipitation | 2 | 1.0 |
Complement 4/*metabolism | 2 | 4.0 |
Complement 4b | 2 | 2.0 |
Complement 1r | 12 | 52.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Monocytes/metabolism | 2 | 0.0 |
Complement/*analysis | 8 | 4.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Complement Activating Enzymes/*metabolism | 3 | 9.0 |
Heat | 2 | 0.0 |
Chemistry | 2 | 0.0 |
Macrophages/*immunology | 2 | 0.0 |
*Receptors, Complement | 2 | 16.0 |
Antigen-Antibody Complex/*analysis | 3 | 1.0 |
Complement 1q | 13 | 12.0 |
Complement 1s | 14 | 63.0 |
Complement Activating Enzymes/immunology | 2 | 20.0 |
Immune Sera | 2 | 0.0 |
Immunoglobulins/metabolism | 2 | 1.0 |
Complement 1/*analysis | 2 | 18.0 |
Complement Activating Enzymes | 2 | 14.0 |
Complement 1 Inactivators/*biosynthesis | 2 | 33.0 |
Complement Activating Enzymes/*biosynthesis | 2 | 28.0 |
Hemolysis | 6 | 1.0 |
Antibodies | 3 | 0.0 |
Antigen-Antibody Complex | 2 | 1.0 |
*Platelet Aggregation | 3 | 3.0 |
*Antigen-Antibody Complex | 3 | 5.0 |
Complement 3/analysis | 8 | 2.0 |
Complement Activating Enzymes/analysis | 4 | 13.0 |
Radioimmunoassay | 2 | 0.0 |
*Plasma Exchange | 2 | 8.0 |
Calcium/pharmacology | 3 | 1.0 |
Complement 1/*physiology | 2 | 40.0 |
Complement Activation/*drug effects | 2 | 2.0 |
Complement 4/analysis | 7 | 3.0 |
Complement Factor B/analysis | 3 | 6.0 |
Antigen-Antibody Complex/*isolation & purification | 2 | 25.0 |
C-Reactive Protein/analysis | 3 | 0.0 |
Complement 5/analysis | 3 | 6.0 |
Child, Preschool | 2 | 0.0 |
Complement 1/analysis | 6 | 12.0 |
Properdin/analysis | 2 | 11.0 |
Child | 2 | 0.0 |
Edetic Acid/pharmacology | 3 | 1.0 |
Complement Fixation Tests | 2 | 2.0 |
Immunoelectrophoresis | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Complement/*analysis/metabolism | 2 | 28.0 |
Amidines/*pharmacology | 2 | 40.0 |
Complement 9/analysis | 2 | 7.0 |
Complement 1 Inactivators | 2 | 28.0 |
Peptides/analysis | 2 | 2.0 |
Complement/*physiology | 2 | 2.0 |
*Complement | 2 | 3.0 |
Histamine Release | 2 | 3.0 |
